Clinical Trial Update: A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adavosertib in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in platinum-sensitive ovarian tumors with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Adavosertib (adavosertib)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-07